Apnimed, Inc. Common Stock

APMD · NASDAQ · Healthcare / Biotechnology

16.92USD+0.29 (+1.74%)

Price History

Full chart

Market Stats

Previous Close16.63

Open17.41

Day Range16.38 – 17.46

52-Week Range16.00 – 35.29

Volume690.80K

Market Cap900.47M

P/E (TTM)3.94

Forward P/E0.00

EPS5.49

Dividend Yield0.00%

50-Day Avg27.39

200-Day Avg27.39

About

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Kevin Robert Lind
Employees81
Headquarters39 John F. Kennedy Street, Cambridge, MA, United States, 02138, USA
Websitehttps://apnimed.com

Leadership

Mr. Kevin Robert LindCEO & Director · b. 1976
Dr. Lawrence G. Miller M.D., M.P.H.Founder & Vice Chair of the Board · b. 1954
Mr. Dennis Patrick Molnar M.B.A.President & COO · b. 1969
Dr. Luigi Taranto Montemurro M.D.Co-Founder & Chief Scientific Officer · b. 1979
Mr. Michael B. KellyChief Financial Officer · b. 1975
Ms. Leila SylvainSenior Manager of Administration
Mr. Steven W. Spector J.D.Chief Legal Officer & Head of Corporate Affairs · b. 1965
Ms. Jennifer PattersonSenior Vice President of Human Resources
Dr. John W. Cronin M.D.Chief Medical Officer · b. 1968
Dr. Sean M. Johnston M.B.A., Ph.D.Consulting Head of CMC · b. 1958

Financials

Income Statement

Currency: USD	2024-12-31	2025-12-31
Total Revenue	8.01M	38.47M
Growth (%)	-	+380.12%
Cost of Revenue	3.37M	6.69M
Gross Profit	4.64M	31.77M
Gross Margin	57.95%	82.60%
Operating Expense	118.88M	85.59M
Operating Income	-114.23M	-53.82M
Operating Margin	-1425.79%	-139.91%
Net Income	-111.31M	-932.00K
Net Income Margin	-1389.23%	-2.42%
R&D	97.38M	62.10M
R&D as % of Total Revenue	1215.36%	161.44%

Balance Sheet

Currency: USD	2024-12-31	2025-12-31
Total Assets	109.22M	72.87M
Total Liabilities	357.84M	445.66M
Total Equity	-248.62M	-372.78M
Cash	68.35M	41.89M

Cash Flow

Currency: USD	2024-12-31	2025-12-31
Operating Cash Flow	-110.21M	-77.83M
Financing Cash Flow	51.00K	51.37M
Capital Expenditure	70.00K	0
Free Cash Flow	-110.28M	-77.83M
FCF to OCF	100.06%	100.00%

Earnings

Report Date	Sep 8, 2026
EPS Estimate	-0.34
EPS Actual	0.51
Surprise	250.00%
Timing	After-hours

Key Statistics & Ratios

Market Cap900.47M

Enterprise Value844.24M

Trailing P/E3.94

Forward P/E0.00

Price / Sales7.82

Price / Book4.40

EPS5.49

Book Value-36.69

Revenue (TTM)115.12M

Gross Profit (TTM)108.10M

EBITDA35.90M

Profit Margin142.10%

Operating Margin-96.89%

Return on Equity0.00%

Return on Assets0.00%

Shares Outstanding41.63M

Shares Float20.46M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Ownership Breakdown

Institutions: 19.70%
Insiders: 35.61%
Retail / Other: 44.69%

Top Fund Holders

Columbia Seligman Tech & Info A
7.20M17.30%
Highland Global Allocation A
405.38K0.97%
abrdn Healthcare Investors
224.84K0.54%
abrdn Healthcare Opportunities
174.88K0.42%
abrdn Life Sciences Investors
112.42K0.27%
abrdn World Healthcare
112.42K0.27%
Principal SmallCap Growth I Instl
91.97K0.22%
Multi-Manager Small Cap Eq Strat Inst
78.15K0.19%
Vanguard MStar Total Stk Mkt Idx Invest
61.79K0.15%
JPM US Small Cap Growth C Acc
37.72K0.09%
JPMorgan American Ord
24.48K0.06%
VALIC Company I Small Cap Value
18.58K0.04%
Franklin Alternative Strategies R6
10.66K0.03%
Vanguard Russell 2000 ETF
7.91K0.02%
SST SA Multi-Managed Small Cap 1
3.57K0.01%
JPMorgan Healthcare Leaders ETF
1.28K0.00%
Vanguard Balanced Index Inv
1.05K0.00%
Vanguard MStar Inst Ttl StkMktIdxInstlPl
9360.00%